ArticleFrontiers in oncology2026
Predictors and prevalence of lateral supraclavicular lymph node metastases on [
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is variability in the coverage of the lateral supraclavicular fossa in adjuvant radiotherapy targets in breast cancer patients. The purpose of this study was to evaluate the prevalence and predictors of lateral supraclavicular lymph node metastasis (LSCLNM) in patients with advanced or multifocal breast cancer on [ Materials and Methods: Invasive ductal breast carcinoma patients who were referred for [ Results: There were 243 patients evaluated, of whom 23 had bilateral disease. Of the 266 primary breast tumors evaluated, 19 (7.1%) cases had ipsilateral LSCLNM. None of the patients with locoregional nodal metastasis limited to axillary levels 1-2 had LSCLNM, whereas 8.7%, 12.8% and 52.2% of cases with axillary nodal metastasis up to level III, axillary nodal plus internal mammary nodal metastases, and medial supraclavicular lymph node metastasis (MSCLNM) showed LSCLNM, respectively. Further associations with LSCLNM included metabolic tumor volume (MTV), tumor location in the upper outer quadrant and presence of distant metastasis. Following multivariate analysis, only MTV and the presence of axillary level III nodal metastasis and MSCLNM remained statistically significant (p of 0.043, 0.011 and <0.001, respectively), suggesting their independence. Conclusions: LSCLNM was identified in a minority of patients with breast cancer undergoing staging with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.